このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Novo Nordisk 将来の成長
Future 基準チェック /36
Novo Nordisk利益と収益がそれぞれ年間14.4%と13.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に65% 15.3%なると予測されています。
主要情報
14.4%
収益成長率
15.3%
EPS成長率
Pharmaceuticals 収益成長 | 23.6% |
収益成長率 | 13.3% |
将来の株主資本利益率 | 65.0% |
アナリストカバレッジ | Good |
最終更新日 | 20 Aug 2024 |
今後の成長に関する最新情報
Recent updates
Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
Sep 22Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Aug 30Novo Nordisk: Denmark's Coca-Cola
Jul 25The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
Jul 11Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
Jun 23業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 406,381 | 149,387 | 118,162 | 163,905 | 22 |
12/31/2025 | 349,334 | 127,974 | 94,213 | 140,958 | 26 |
12/31/2024 | 290,128 | 101,959 | 74,396 | 122,755 | 26 |
6/30/2024 | 258,003 | 89,898 | 66,027 | 115,334 | N/A |
3/31/2024 | 244,243 | 89,276 | 50,304 | 93,408 | N/A |
12/31/2023 | 232,261 | 83,683 | 70,012 | 108,908 | N/A |
9/30/2023 | 214,490 | 75,312 | 77,825 | 106,458 | N/A |
6/30/2023 | 201,325 | 67,239 | 67,497 | 89,731 | N/A |
3/31/2023 | 188,290 | 61,129 | 67,341 | 85,115 | N/A |
12/31/2022 | 176,954 | 55,525 | 64,134 | 78,887 | N/A |
9/30/2022 | 167,195 | 52,825 | 57,875 | 68,769 | N/A |
6/30/2022 | 157,251 | 50,539 | 57,680 | 66,037 | N/A |
3/31/2022 | 149,027 | 49,344 | 59,665 | 67,331 | N/A |
12/31/2021 | 140,800 | 47,757 | 47,615 | 55,000 | N/A |
9/30/2021 | 134,605 | 46,183 | 40,213 | 58,189 | N/A |
6/30/2021 | 129,910 | 44,362 | 31,814 | 54,188 | N/A |
3/31/2021 | 126,875 | 42,864 | 31,337 | 53,194 | N/A |
12/31/2020 | 126,946 | 42,138 | 29,870 | 51,951 | N/A |
9/30/2020 | 127,225 | 41,537 | 44,800 | 56,944 | N/A |
6/30/2020 | 126,575 | 41,433 | 47,621 | 56,126 | N/A |
3/31/2020 | 126,605 | 40,403 | 36,987 | 46,904 | N/A |
12/31/2019 | 122,021 | 38,951 | 35,551 | 46,782 | N/A |
9/30/2019 | 119,336 | 38,731 | 36,785 | 49,029 | N/A |
6/30/2019 | 116,821 | 37,574 | 31,251 | 43,960 | N/A |
3/31/2019 | 114,192 | 38,322 | 32,202 | 44,691 | N/A |
12/31/2018 | 111,831 | 38,628 | 32,206 | 44,616 | N/A |
9/30/2018 | 110,091 | 38,384 | 31,576 | 43,236 | N/A |
6/30/2018 | 108,943 | 39,117 | 33,787 | 44,538 | N/A |
3/31/2018 | 110,174 | 38,725 | N/A | 38,885 | N/A |
12/31/2017 | 111,696 | 38,130 | N/A | 41,168 | N/A |
9/30/2017 | 113,276 | 38,576 | N/A | 46,289 | N/A |
6/30/2017 | 114,199 | 38,609 | N/A | 48,557 | N/A |
3/31/2017 | 113,020 | 38,626 | N/A | 52,937 | N/A |
12/31/2016 | 111,780 | 37,925 | N/A | 48,314 | N/A |
9/30/2016 | 111,084 | 37,484 | N/A | 47,280 | N/A |
6/30/2016 | 110,339 | 36,064 | N/A | 44,179 | N/A |
3/31/2016 | 109,939 | 34,439 | N/A | 41,656 | N/A |
12/31/2015 | 107,927 | 34,860 | N/A | 38,287 | N/A |
9/30/2015 | 103,636 | 33,131 | N/A | 35,469 | N/A |
6/30/2015 | 99,093 | 31,248 | N/A | 35,578 | N/A |
3/31/2015 | 93,663 | 29,899 | N/A | 31,729 | N/A |
12/31/2014 | 88,806 | 26,481 | N/A | 31,692 | N/A |
9/30/2014 | 85,919 | 26,005 | N/A | 29,763 | N/A |
6/30/2014 | 84,181 | 25,920 | N/A | 23,783 | N/A |
3/31/2014 | 83,932 | 25,660 | N/A | 22,941 | N/A |
12/31/2013 | 83,572 | 25,184 | N/A | 25,942 | N/A |
9/30/2013 | 82,836 | 24,886 | N/A | 22,084 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: NVOの予測収益成長率 (年間14.4% ) は 貯蓄率 ( 2.5% ) を上回っています。
収益対市場: NVOの収益 ( 14.4% ) US市場 ( 15.2% ) よりも低い成長が予測されています。
高成長収益: NVOの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: NVOの収益 ( 13.3% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。
高い収益成長: NVOの収益 ( 13.3% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: NVOの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 65 %)。